Loading…
T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen
Background To achieve T-downstaging and better resectability in locally advanced rectal cancer, neoadjuvant radiochemotherapy (RCT) has become the current standard of treatment. A variety of schemes have been used. This study investigates which scheme had the best effect on these parameters. Methods...
Saved in:
| Published in: | Annals of surgical oncology 2012-02, Vol.19 (2), p.392-401 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543 |
| container_end_page | 401 |
| container_issue | 2 |
| container_start_page | 392 |
| container_title | Annals of surgical oncology |
| container_volume | 19 |
| creator | Martijnse, Ingrid S. Dudink, Ralph L. Kusters, Miranda Vermeer, Thomas A. West, Nicholas P. Nieuwenhuijzen, Grard A. van Lijnschoten, Ineke Martijn, Hendrik Creemers, Geert-Jan Lemmens, Valery E. van de Velde, Cornelis J. Sebag-Montefiore, David Glynne-Jones, Robert Quirke, Phil Rutten, Harm J. |
| description | Background
To achieve T-downstaging and better resectability in locally advanced rectal cancer, neoadjuvant radiochemotherapy (RCT) has become the current standard of treatment. A variety of schemes have been used. This study investigates which scheme had the best effect on these parameters.
Methods
Our institution is a referral center for locally advanced rectal cancer. Different neoadjuvant radiochemotherapy regimens were administered: long course radiotherapy (RTH), 5-FU and leucovorin (5FUBolus), a combination of capecitabine and oxaliplatin (CORE), and capecitabine only (CAP). Selection of patients for 1 of the regimens was based on hospital policy rather than patient or tumor characteristics.
Results
The data of 504 consecutive patients (
n
= 181 T3+,
n
= 323 T4) without metastatic disease (cM0) who underwent surgery for advanced rectal carcinoma between 1994 and 2010 were reviewed. The RTH, 5FUBolus, CORE, and CAP scheme were administered to 106, 137, 155, and 106 patients, respectively. Odds ratios for downstaging were less effective for RTH, 5FUBolus, and CAP (0.31, 0.44, and 0.31;
P
|
| doi_str_mv | 10.1245/s10434-011-1955-1 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_917854406</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2568193991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543</originalsourceid><addsrcrecordid>eNp1kUtv1DAUhSMEoqXwA9ggiw0LFPCNX8myHbUFqaKoDGvLse-0GSX2YDuolfrj6zAFJCRWftzvnOvrU1WvgX6AhouPCShnvKYANXRC1PCkOgRRbrhs4WnZU9nWXSPFQfUipS2loBgVz6uDBlTXCCoPq_s1e0-Md2TNyRXabEayMt5iJF9NHtDnRL4hTiQHcoIeN0MmZzGU8w2SY-eGPARPwoZc3ppx2I1F4xd2KX_BYNx2_ml8JqsbnEI0bjC_BFd4PUzoX1bPNmZM-OpxPaq-n52uV5_qi8vzz6vji9oyRXONChrW9H1rRRkAsFVGUdZT7gRHKxuuDEjGykTWta3rmeutpMp1ri2fITg7qt7tfXcx_JgxZT0NyeI4Go9hTroD1QrOqSzk23_IbZijL49bIAYSWlUg2EM2hpQibvQuDpOJdxqoXoLR-2B0CUYvwWgomjePxnM_ofuj-J1EAZo9kErJX2P82_n_rg_4DJbE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>917316187</pqid></control><display><type>article</type><title>T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen</title><source>Springer Nature</source><creator>Martijnse, Ingrid S. ; Dudink, Ralph L. ; Kusters, Miranda ; Vermeer, Thomas A. ; West, Nicholas P. ; Nieuwenhuijzen, Grard A. ; van Lijnschoten, Ineke ; Martijn, Hendrik ; Creemers, Geert-Jan ; Lemmens, Valery E. ; van de Velde, Cornelis J. ; Sebag-Montefiore, David ; Glynne-Jones, Robert ; Quirke, Phil ; Rutten, Harm J.</creator><creatorcontrib>Martijnse, Ingrid S. ; Dudink, Ralph L. ; Kusters, Miranda ; Vermeer, Thomas A. ; West, Nicholas P. ; Nieuwenhuijzen, Grard A. ; van Lijnschoten, Ineke ; Martijn, Hendrik ; Creemers, Geert-Jan ; Lemmens, Valery E. ; van de Velde, Cornelis J. ; Sebag-Montefiore, David ; Glynne-Jones, Robert ; Quirke, Phil ; Rutten, Harm J.</creatorcontrib><description>Background
To achieve T-downstaging and better resectability in locally advanced rectal cancer, neoadjuvant radiochemotherapy (RCT) has become the current standard of treatment. A variety of schemes have been used. This study investigates which scheme had the best effect on these parameters.
Methods
Our institution is a referral center for locally advanced rectal cancer. Different neoadjuvant radiochemotherapy regimens were administered: long course radiotherapy (RTH), 5-FU and leucovorin (5FUBolus), a combination of capecitabine and oxaliplatin (CORE), and capecitabine only (CAP). Selection of patients for 1 of the regimens was based on hospital policy rather than patient or tumor characteristics.
Results
The data of 504 consecutive patients (
n
= 181 T3+,
n
= 323 T4) without metastatic disease (cM0) who underwent surgery for advanced rectal carcinoma between 1994 and 2010 were reviewed. The RTH, 5FUBolus, CORE, and CAP scheme were administered to 106, 137, 155, and 106 patients, respectively. Odds ratios for downstaging were less effective for RTH, 5FUBolus, and CAP (0.31, 0.44, and 0.31;
P
< .0001) when compared with the CORE scheme. Odds ratios for a R1 resection (3.74, 1.94, 1.14;
P
= .003) or CRM+ resection (3.78, 2.73, 1.34;
P
= .001) were also in favor of the CORE. Hazard ratios for CSS were significantly better for the CORE scheme.
Conclusions
Downstaging with neoadjuvant treatment results in an increased number of radical resections. In our study, the combination of capecitabine and oxaliplatin appears to be the most effective regimen for locally advanced rectal cancer tumors. However, longer follow-up will be necessary to confirm this conclusion.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/s10434-011-1955-1</identifier><identifier>PMID: 21792506</identifier><language>eng</language><publisher>New York: Springer-Verlag</publisher><subject><![CDATA[Adenocarcinoma - mortality ; Adenocarcinoma - secondary ; Adenocarcinoma - therapy ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Capecitabine ; Chemoradiotherapy ; Colorectal Cancer ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; Follow-Up Studies ; Humans ; Leucovorin - administration & dosage ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Oncology ; Organoplatinum Compounds - administration & dosage ; Preoperative Care ; Prospective Studies ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Rectal Neoplasms - therapy ; Surgery ; Surgical Oncology ; Survival Rate ; Treatment Outcome]]></subject><ispartof>Annals of surgical oncology, 2012-02, Vol.19 (2), p.392-401</ispartof><rights>Society of Surgical Oncology 2011</rights><rights>Society of Surgical Oncology 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543</citedby><cites>FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21792506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martijnse, Ingrid S.</creatorcontrib><creatorcontrib>Dudink, Ralph L.</creatorcontrib><creatorcontrib>Kusters, Miranda</creatorcontrib><creatorcontrib>Vermeer, Thomas A.</creatorcontrib><creatorcontrib>West, Nicholas P.</creatorcontrib><creatorcontrib>Nieuwenhuijzen, Grard A.</creatorcontrib><creatorcontrib>van Lijnschoten, Ineke</creatorcontrib><creatorcontrib>Martijn, Hendrik</creatorcontrib><creatorcontrib>Creemers, Geert-Jan</creatorcontrib><creatorcontrib>Lemmens, Valery E.</creatorcontrib><creatorcontrib>van de Velde, Cornelis J.</creatorcontrib><creatorcontrib>Sebag-Montefiore, David</creatorcontrib><creatorcontrib>Glynne-Jones, Robert</creatorcontrib><creatorcontrib>Quirke, Phil</creatorcontrib><creatorcontrib>Rutten, Harm J.</creatorcontrib><title>T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><addtitle>Ann Surg Oncol</addtitle><description>Background
To achieve T-downstaging and better resectability in locally advanced rectal cancer, neoadjuvant radiochemotherapy (RCT) has become the current standard of treatment. A variety of schemes have been used. This study investigates which scheme had the best effect on these parameters.
Methods
Our institution is a referral center for locally advanced rectal cancer. Different neoadjuvant radiochemotherapy regimens were administered: long course radiotherapy (RTH), 5-FU and leucovorin (5FUBolus), a combination of capecitabine and oxaliplatin (CORE), and capecitabine only (CAP). Selection of patients for 1 of the regimens was based on hospital policy rather than patient or tumor characteristics.
Results
The data of 504 consecutive patients (
n
= 181 T3+,
n
= 323 T4) without metastatic disease (cM0) who underwent surgery for advanced rectal carcinoma between 1994 and 2010 were reviewed. The RTH, 5FUBolus, CORE, and CAP scheme were administered to 106, 137, 155, and 106 patients, respectively. Odds ratios for downstaging were less effective for RTH, 5FUBolus, and CAP (0.31, 0.44, and 0.31;
P
< .0001) when compared with the CORE scheme. Odds ratios for a R1 resection (3.74, 1.94, 1.14;
P
= .003) or CRM+ resection (3.78, 2.73, 1.34;
P
= .001) were also in favor of the CORE. Hazard ratios for CSS were significantly better for the CORE scheme.
Conclusions
Downstaging with neoadjuvant treatment results in an increased number of radical resections. In our study, the combination of capecitabine and oxaliplatin appears to be the most effective regimen for locally advanced rectal cancer tumors. However, longer follow-up will be necessary to confirm this conclusion.</description><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - secondary</subject><subject>Adenocarcinoma - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Capecitabine</subject><subject>Chemoradiotherapy</subject><subject>Colorectal Cancer</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Leucovorin - administration & dosage</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Preoperative Care</subject><subject>Prospective Studies</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - therapy</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kUtv1DAUhSMEoqXwA9ggiw0LFPCNX8myHbUFqaKoDGvLse-0GSX2YDuolfrj6zAFJCRWftzvnOvrU1WvgX6AhouPCShnvKYANXRC1PCkOgRRbrhs4WnZU9nWXSPFQfUipS2loBgVz6uDBlTXCCoPq_s1e0-Md2TNyRXabEayMt5iJF9NHtDnRL4hTiQHcoIeN0MmZzGU8w2SY-eGPARPwoZc3ppx2I1F4xd2KX_BYNx2_ml8JqsbnEI0bjC_BFd4PUzoX1bPNmZM-OpxPaq-n52uV5_qi8vzz6vji9oyRXONChrW9H1rRRkAsFVGUdZT7gRHKxuuDEjGykTWta3rmeutpMp1ri2fITg7qt7tfXcx_JgxZT0NyeI4Go9hTroD1QrOqSzk23_IbZijL49bIAYSWlUg2EM2hpQibvQuDpOJdxqoXoLR-2B0CUYvwWgomjePxnM_ofuj-J1EAZo9kErJX2P82_n_rg_4DJbE</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Martijnse, Ingrid S.</creator><creator>Dudink, Ralph L.</creator><creator>Kusters, Miranda</creator><creator>Vermeer, Thomas A.</creator><creator>West, Nicholas P.</creator><creator>Nieuwenhuijzen, Grard A.</creator><creator>van Lijnschoten, Ineke</creator><creator>Martijn, Hendrik</creator><creator>Creemers, Geert-Jan</creator><creator>Lemmens, Valery E.</creator><creator>van de Velde, Cornelis J.</creator><creator>Sebag-Montefiore, David</creator><creator>Glynne-Jones, Robert</creator><creator>Quirke, Phil</creator><creator>Rutten, Harm J.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen</title><author>Martijnse, Ingrid S. ; Dudink, Ralph L. ; Kusters, Miranda ; Vermeer, Thomas A. ; West, Nicholas P. ; Nieuwenhuijzen, Grard A. ; van Lijnschoten, Ineke ; Martijn, Hendrik ; Creemers, Geert-Jan ; Lemmens, Valery E. ; van de Velde, Cornelis J. ; Sebag-Montefiore, David ; Glynne-Jones, Robert ; Quirke, Phil ; Rutten, Harm J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - secondary</topic><topic>Adenocarcinoma - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Capecitabine</topic><topic>Chemoradiotherapy</topic><topic>Colorectal Cancer</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Leucovorin - administration & dosage</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Preoperative Care</topic><topic>Prospective Studies</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - therapy</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martijnse, Ingrid S.</creatorcontrib><creatorcontrib>Dudink, Ralph L.</creatorcontrib><creatorcontrib>Kusters, Miranda</creatorcontrib><creatorcontrib>Vermeer, Thomas A.</creatorcontrib><creatorcontrib>West, Nicholas P.</creatorcontrib><creatorcontrib>Nieuwenhuijzen, Grard A.</creatorcontrib><creatorcontrib>van Lijnschoten, Ineke</creatorcontrib><creatorcontrib>Martijn, Hendrik</creatorcontrib><creatorcontrib>Creemers, Geert-Jan</creatorcontrib><creatorcontrib>Lemmens, Valery E.</creatorcontrib><creatorcontrib>van de Velde, Cornelis J.</creatorcontrib><creatorcontrib>Sebag-Montefiore, David</creatorcontrib><creatorcontrib>Glynne-Jones, Robert</creatorcontrib><creatorcontrib>Quirke, Phil</creatorcontrib><creatorcontrib>Rutten, Harm J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martijnse, Ingrid S.</au><au>Dudink, Ralph L.</au><au>Kusters, Miranda</au><au>Vermeer, Thomas A.</au><au>West, Nicholas P.</au><au>Nieuwenhuijzen, Grard A.</au><au>van Lijnschoten, Ineke</au><au>Martijn, Hendrik</au><au>Creemers, Geert-Jan</au><au>Lemmens, Valery E.</au><au>van de Velde, Cornelis J.</au><au>Sebag-Montefiore, David</au><au>Glynne-Jones, Robert</au><au>Quirke, Phil</au><au>Rutten, Harm J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen</atitle><jtitle>Annals of surgical oncology</jtitle><stitle>Ann Surg Oncol</stitle><addtitle>Ann Surg Oncol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>19</volume><issue>2</issue><spage>392</spage><epage>401</epage><pages>392-401</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Background
To achieve T-downstaging and better resectability in locally advanced rectal cancer, neoadjuvant radiochemotherapy (RCT) has become the current standard of treatment. A variety of schemes have been used. This study investigates which scheme had the best effect on these parameters.
Methods
Our institution is a referral center for locally advanced rectal cancer. Different neoadjuvant radiochemotherapy regimens were administered: long course radiotherapy (RTH), 5-FU and leucovorin (5FUBolus), a combination of capecitabine and oxaliplatin (CORE), and capecitabine only (CAP). Selection of patients for 1 of the regimens was based on hospital policy rather than patient or tumor characteristics.
Results
The data of 504 consecutive patients (
n
= 181 T3+,
n
= 323 T4) without metastatic disease (cM0) who underwent surgery for advanced rectal carcinoma between 1994 and 2010 were reviewed. The RTH, 5FUBolus, CORE, and CAP scheme were administered to 106, 137, 155, and 106 patients, respectively. Odds ratios for downstaging were less effective for RTH, 5FUBolus, and CAP (0.31, 0.44, and 0.31;
P
< .0001) when compared with the CORE scheme. Odds ratios for a R1 resection (3.74, 1.94, 1.14;
P
= .003) or CRM+ resection (3.78, 2.73, 1.34;
P
= .001) were also in favor of the CORE. Hazard ratios for CSS were significantly better for the CORE scheme.
Conclusions
Downstaging with neoadjuvant treatment results in an increased number of radical resections. In our study, the combination of capecitabine and oxaliplatin appears to be the most effective regimen for locally advanced rectal cancer tumors. However, longer follow-up will be necessary to confirm this conclusion.</abstract><cop>New York</cop><pub>Springer-Verlag</pub><pmid>21792506</pmid><doi>10.1245/s10434-011-1955-1</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2012-02, Vol.19 (2), p.392-401 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_917854406 |
| source | Springer Nature |
| subjects | Adenocarcinoma - mortality Adenocarcinoma - secondary Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Capecitabine Chemoradiotherapy Colorectal Cancer Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Follow-Up Studies Humans Leucovorin - administration & dosage Male Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy Neoplasm Staging Oncology Organoplatinum Compounds - administration & dosage Preoperative Care Prospective Studies Rectal Neoplasms - mortality Rectal Neoplasms - pathology Rectal Neoplasms - therapy Surgery Surgical Oncology Survival Rate Treatment Outcome |
| title | T3+ and T4 Rectal Cancer Patients Seem to Benefit From the Addition of Oxaliplatin to the Neoadjuvant Chemoradiation Regimen |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=T3+%20and%20T4%20Rectal%20Cancer%20Patients%20Seem%20to%20Benefit%20From%20the%20Addition%20of%20Oxaliplatin%20to%20the%20Neoadjuvant%20Chemoradiation%20Regimen&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Martijnse,%20Ingrid%20S.&rft.date=2012-02-01&rft.volume=19&rft.issue=2&rft.spage=392&rft.epage=401&rft.pages=392-401&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/s10434-011-1955-1&rft_dat=%3Cproquest_cross%3E2568193991%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c370t-e71232bb8c51731e87a703b04d54ec6247a1633925cd88db3dbc607d9d8534543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=917316187&rft_id=info:pmid/21792506&rfr_iscdi=true |